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PELAPORAN KESAN MUDARAT UBAT OLEH KONSUMER DALAM 
NEGERI PULAU PINANG, MALAYSIA: 
PERSPEKTIF PROFESIONAL KESIHATAN DAN KONSUMER 
  
ABSTRAK 
Pemonitoran kesan mudarat ubat adalah perlu untuk mengurangkan atau mencegah 
bahaya kepada pesakit yang berpunca daripada ubat-ubatan yang mereka ambil. 
Pertama, kajian ini membandingkan sistem ubat di Malaysia, Australia dan Sweden 
serta menilai beberapa aspek penting dalam kalangan profesional kesihatan terhadap 
kesan mudarat ubat dan farmakovigilans.  Analisis perbandingan telah menggunakan 
Model Leavitt’s Diamond yang telah disesuaikan oleh Scott dalam beberapa 
komponen. Struktur, proses dan hasil akhir sistem keselamatan ubat di ketiga-tiga 
negara digunakan sebagai pembolehubah dan ukuran hasil akhir. Kemudian kajian 
kes telah dijalankan di Pusat Sejahtera, Universiti Sains Malaysia melibatkan 
profesional kesihatan dan pesakit. Akhir sekali, kajian ini meneliti persepsi orang 
ramai tentang kesan mudarat ubat dan menilai persepsi doktor klinik swasta dan ahli 
farmasi komuniti di Pulau Pinang tentang pelaporan kesan mudarat ubat oleh 
konsumer.  Kajian ini menggunakan kedua-dua kaedah kajian kualitatif dan 
kuantitatif.  Penyelidik menggunakan soal selidik yang telah disahkan dalam 
kajiselidik dalam kalangan profesional kesihatan dan orang ramai.  Data dan 
maklumat telah dikumpul secara bersemuka dengan responden dan mel.   Kaedah 
statistik deskriptif dan inferensi bukan parametrik telah digunakan dalam analisis; 
paras alfa adalah 0.05.  Keputusan kajian menunjukkan sistem di ketiga-tiga negara 
adalah berbeza dari segi keperluan laporan, pengurusan laporan, sumber yang 
dibelanjakan dan pertukaran maklumat.   Australia dan Sweden mempunyai 
pelaporan oleh konsumer yang betul dalam sistem keselamatan ubat dan negara-
negara ini mempunyai pelaporan kesan mudarat dan penglibatan konsumer yang 
 xiv 
 
lebih berkesan berbanding Malaysia. Dapatan kajian kes di Pusat Sejahtera 
menyarankan kebolehlaksanaan untuk membangunkan program farmakovigilans di 
universiti bagi pelaporan kesan mudarat ubat oleh konsumer. Tahap pengetahuan 
yang lemah dalam kalangan profesional kesihatan dan konsumer menyarankan 
perlunya intervensi pendidikan dan strategi penambahbaikan bagi memudahkan 
mekanisme pelaporan.  Daripada 500 orang awam yang disoalselidik,  230 (46%) 
adalah lelaki dan 270 (54%) perempuan.  Lebih daripada satu pertiga (38.2%) tidak 
tahu definisi kesan mudarat ubat dan 52.6% tidak boleh membezakan antara kesan 
mudarat dan kesan sampingan ubat. Sebaliknya, ramai responden mampu 
mengaitkan kesan mudarat ubat dengan situasi seharian berdasarkan pengalaman 
mereka (54.2%), dan hanya 48.2% dakwa doktor dan ahli farmasi ada menyuruh 
mereka melaporkan kesan mudarat ubat.  Responden bersetuju tentang dua perkara: 
iaitu setiap orang tidak kira umur boleh mengalami kesan mudarat ubat (60.8%) dan 
pengumpulan data kesan mudarat ubat (96.4%) adalah sangat penting.  Doktor klinik 
swasta dan ahli farmasi komuniti sedar tentang kepentingan dan faedah laporan oleh 
konsumer; 88% merasakan pelaporan sebegitu akan membawa lebih faedah kepada 
program farmakovigilans sedia ada.  Pelaporan ini akan menambah lebih faedah 
kepada program sedia ada di Malaysia, walaupun terdapat rintangan dalam kalangan 
responden yang sangsi bahawa pesakit boleh menulis laporan yang sah serupa 
dengan laporan ahli profesional kesihatan. Ringkasnya, laporan kesan mudarat ubat 
di Malaysia perlu ditambahbaik dengan meningkatkan tahap kesedaran kesemua 
pemegang taruh dalam sistem penjagaan kesihatan.  Konsumer perlu lebih 
pendidikan tentang ubat-ubatan mereka, bagaimana untuk mengesahkan sebarang 
komplain tentang penggunaan ubat, bagaimana untuk melaporkan dengan betul dan 
menyalurkan ia kepada individu atau badan yang betul.    
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ADVERSE DRUG REACTIONS REPORTING BY CONSUMERS IN THE 
STATE OF PENANG, MALAYSIA: 
PERSPECTIVES FROM HEALTHCARE PROFESSIONALS AND 
CONSUMERS 
 
 
ABSTRACT 
It is essential to monitor adverse drug reactions (ADRs) in order to minimize or 
prevent harm to patients arising from their medicines. This study first compares the 
drug systems used in Malaysia, Australia and Sweden, and assessing several 
substantial aspects among the professionals in healthcare against ADR and 
pharmacovigilance.  A comparative analysis that makes use of Leavitt’s Diamond 
Model has been adapted by Scott in terms of several components.  The structure, 
process and the outcome of the drugs’ safety system in all three countries become the 
variables and outcome measure in this research. Then a case study was conducted 
involving healthcare professionals and patients at the University Wellness Center 
(UWC), Universiti Sains Malaysia. Finally, this study explores the perceptions of the 
public on ADRs and assessing the perceptions of the GPs (general practitioners) and 
the community pharmacists on consumers’ ADR reporting in Penang. This study 
used both qualitative and quantitative research methods. The researcher utilized 
validated questionnaire in the survey among healthcare professionals and public.  
Both face-to-face and mail survey methods were used to gather data and information. 
Descriptive and non-parametric inferential statistics were utilized for analysis; alpha 
level used was 0.05.  Findings show that the systems of the three countries are 
different with regards to reporting requirements, report handling, resources spent and 
the exchange of information in the environment.  Australia and Sweden have proper  
consumer reporting  in drug safety systems and these countries have more effective 
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ADR reporting and consumer involvement than in Malaysia. The findings of the case 
study in UWC suggest the feasibility for establishing a university based 
pharmacovigilance program for consumer reporting.  Poor knowledge among the 
HCPs and consumers suggests the urgent need for educational interventions among 
HCPs in UWC and improvement of strategies to ease the reporting mechanisms.  
From 500 general public surveyed, 230 (46%) are male and 270 (54%) female.  More 
than one-third (38.2%) do not know the definition of ADRs and 52.6% cannot 
differentiate between an ADR and  side effects.   In turn, a lot of the respondents 
have been able to link ADRs with real-life situations based on their experiences 
(54.2%), and only 48.2% claim that physicians and pharmacists did ask them to file 
ADR reports.   They are in agreement about two things: that everyone, regardless of 
age, can suffer from ADRs (60.8%); and data collection on ADRs (96.4%) is very 
important.  The GPs and CPs were aware about the importance and benefits of 
consumer reporting; 88% feel that such a reporting will bring more benefits to the 
existing pharmacovigilance programme. Such reporting will add more benefits to the 
existing programmes in Malaysia, although the barrier was the perception that 
respondents doubted if the patients can write valid reports similar to HCP reports. In 
summary, ADR reporting in Malaysia needs to be improved by increasing the level 
of awareness of all stakeholders in the healthcare system. The consumers need more 
education about their medications, how to validate any complaints they have about 
the drug consumption, how to file a proper report and channel it to the ‘right’ person 
or bodies.
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CHAPTER 1 
INTRODUCTION 
 
1.1 Introduction  
Every medication is potentially hazardous and can cause substantial harm to 
the recipient with varying degree of injury.  One of the potential hazards that 
accompany the use of most types of medications is Adverse Drug Reactions (ADRs). 
ADRs can cause short- and long-term hospitalization, morbidity and even can lead to 
mortality (WHO, 1972).   
The World Health Organization (1972) defines an ADR as ‘any response to a 
drug that is noxious and unintended, and that occurs at doses used in humans for 
prophylaxis, diagnosis, or therapy, excluding failure to accomplish the intended 
purpose’ (Lee and Thomas, 2003). The WHO reported that ADRs are responsible for 
a significant number of hospital admissions with reports ranging from 0.3% to 11% 
of overall hospitalizations (WHO Collaborating Centre for International Drug 
Monitoring, 2002). For instance, it has been estimated that over 770,000 people are 
injured or die each year from adverse drug events (Classen, et al., 1997). A 
commonly quoted meta-analysis performed in the United States (US) indicated that 
ADRs were between the fourth and sixth most common cause of death in 1997 
(Lazarou et al., 1998), suggesting a major consideration for the entire healthcare 
system.  
Hospital admissions due to ADRs have been reported as 300,000 admissions 
per year in the United States (Atkin et al., 1995), and accounted for 6.5% of total 
hospital admissions (Jha et al., 2001); in Canada 12% of hospital admissions were 
reported due to ADRs  (Grymonpre et al., 1988); in the UK 6.5% of hospital 
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admissions were related to ADRs, with the ADR directly leading to admission in 
80% of these cases (Pirmohamed, 2004);  13% of hospital admissions in France, 
(Pouyanne et al., 2000); in India  6.7% of hospital admissions (Malhota et al., 2001); 
and the worldwide reports range at an average between 0.2-21.7% of  overall hospital 
admissions   (Einarson, 1993).  
Looking at the scenario of ADRs in developing countries, only a few studies 
have examined the rate of ADRs in developing countries. A prospective 
observational study from Iran found 11.8% of patients had experienced at least one 
ADR (Pourseyed et al., 2009). In another study from Iran, approximately 16.8% of 
patients had at least one ADR and 2.9% of the ADRs were identified as ‘lethal’ 
(Gholami and Shalviri, 1999). A study from South India reported an overall 
incidence of 9.8%. This included 3.4% ADR-related admissions and 3.7% of ADRs 
that occurred during the hospital stay (Arulmani et al., 2008). In Nepal, the 
prevalence of ADRs was 0.86%, the male to female ratio was 0.85, and 10.81% of 
the ADRs were considered ‘severe’ (Jha et al., 2007).  
The mortality due to ADRs is also a substantial problem. For instance, deaths 
due to ADRs in the US amount to 160,000 deaths annually (Shapiro et al., 1971); in 
the UK, the corresponding figure was 1044 deaths (Eaton, 2002). In France ADRs 
accounted for 0.12% of deaths (Pouyanne et al., 2000), and in Germany 1.6% deaths 
of hospital admissions (Riettling, 2000).  
The above statistics on hospitalization and mortality due to ADRs highlight the 
fact that it is essential to monitor ADRs in order to minimize or prevent harm to 
patients arising from their medicines; to detect ADRs before they are clinically 
manifested, and to obtain more knowledge to ensure safe use of medicines, and to 
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assess the harms, benefits, and risks of available drugs (WHO Collaborating Centre 
for International Drug Monitoring, 2002).  
During the past decade concerns over ADRs have widened to include herbal, 
traditional and complementary medicines, blood products, biological agents, medical 
devices, and vaccines (WHO Collaborating Centre for International Drug 
Monitoring, 2002). A few other areas are also of relevance to pharmacovigilance 
(which the study will be focusing on in later paragraphs), including substandard 
medicines, medication errors, lack of accurate reports, use of medicines for 
indications that are not approved and for which there is inadequate scientific basis, 
case reports of acute and chronic poisoning, assessment of drug-related mortality, 
abuse and misuse of medicines, and adverse interactions of medicines with 
chemicals, other medicines, and food. Thus, the science of safety monitoring should 
not be viewed only as a mere study on ADRs but rather should enclose the broad 
perspective of patient safety during the healthcare process.  
On examining from the chronological perspective, this subject first appeared 
on the medical scene 50 years ago. Following the thalidomide disaster in the 1960s, 
which resulted in embryonic malformations in thousands of children whose mothers 
had used drugs during pregnancy, interest in the safety of medicine emerged.  
In the 1960s, the WHO began the global monitoring of the safety of drugs 
and highlighted the need for pharmacovigilance because the information that was 
gathered before marketing any specific drug has always been incomplete (WHO 
Collaborating Centre for International Drug Monitoring, 2002) . In response to this, 
according to Olsson (2001), pharmacovigilance has been established in most 
countries, and it is ‘the science relating to the detection, assessment, understanding 
and prevention of adverse effects or any other possible drug-related problems.’ 
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Testing the effects of a medicine on animals cannot be used as evidence for toxicity 
in human beings, and any tests carried out on the latter during clinical trials involve 
only small numbers. Therefore, the effects of a medicine can only be assessed 
properly when the drug is widely used, and differences among countries may occur 
(WHO Collaborating Centre for International Drug Monitoring, 2002).   
 
1.2 Pharmacovigilance and the human’s rights  
Pharmacovigilance may have stemmed from the awareness that the highest 
level of health standard is one of the basic human rights, as suggested in the 
declaration of Alma-Ata [Declaration of Alma-Ata,1978].  The term ‘Health’ does 
not only mean that the services of the health system must be available to all 
according to their needs, and does not depend only on the results of treatment, but 
also equally important, is the course of this process, for example, transparency, 
participation, equality, and fairness  (Hunt and Beckman, 2008). Access to health 
services and information and the right to the highest attainable standards of health 
and health information enhance the health of both individuals and communities. A 
degree of transparency ensures that all key partners including the patients, the public 
and private sectors, international organizations and civil organizations will receive 
the correct treatment.  
Similarly, the participation of everyone on issues that affect and have an impact 
on human health is a right for all, and includes participation in defining strategies, 
development, and policy-making, implementation and accountability, according to 
the declaration of Alma-Ata [Declaration of Alma-Ata, 1978].  Fairness and equality 
are among the most basic elements of international human rights (Hunt and 
Beckman, 2008).   
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1.3 Need for local pharmacovigilance programs in every country  
Although there has been an International Drug Monitoring Program coordinated by 
WHO, still there is definite need for indigenous pharmacovigilance programs. It is 
because differences exist among countries (and even regions within countries) in the 
occurrence of ADRs and other drug-related problems. This may be due to the 
existence of differences in disease, prescribing practices, genetics, diet, traditions, 
drug manufacturing processes, which influence pharmaceutical quality and 
composition, and drug distribution and use, including indications, dose and 
availability of medicines (Olsson, 2001).   
In addition, the use of traditional and complementary drugs may pose specific 
toxicological problems, when used alone or in combination with other drugs. Hence, 
data derived from within a country or region may have greater relevance and 
educational value and may encourage national regulatory decision making. 
Information obtained in one country (e.g., the country of origin of the drug) may not 
be relevant to other parts of the world, where circumstances may differ. Therefore, 
drug monitoring is of tremendous value as a tool for detecting ADRs and specifically 
in relation to counterfeit and substandard quality products. ADR monitoring helps 
ensure that patients obtain safe and efficacious products. 
 
1.4 Drug regulation in Malaysia   
In the Malaysian context, pharmaceuticals are regulated by the Drug Control 
Authority (DCA) under the control of the Drugs and Cosmetics Regulation Law 
passed in 1984. The DCA is managed by the Director General of Health, the Director 
of Pharmaceutical Services, the Director of the National Pharmaceutical Control 
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Laboratory and seven appointed members. It is the responsibility of the DCA to 
ensure the safety, quality, and efficacy of pharmaceuticals in Malaysia. Some of its 
duties include reviewing registration applications for drugs and cosmetics, licensing 
importers, manufacturers, and wholesalers, postmarketing safety surveillance of 
medicines, and ADR monitoring. (“BPFK”, 2013). 
 
1.5 Existing pharmacovigilance program in Malaysia   
Malaysia has a well established national centre of pharmacovigilance, namely the 
National Adverse Drug Reaction Monitoring Centre, which has a national coverage. 
Some major hospitals and pharmaceutical companies also operate ADR monitoring 
systems under it. One can report ADR either directly to the national center or through 
the hospitals and pharmaceutical companies that run pharmacovigilance programs 
which are then consolidated at the national center. Reports from doctors, pharmacists 
and dentists are made on a voluntary basis but reports from marketing authorization 
holders are mandatory. The centre monitors drugs for human use, vaccines, 
biological and herbal remedies, using prepaid postage report forms or report cards 
that are updated every month. It also records ADRs manually, and has a local 
database. The national centre has an advisory committee that assesses the causality of 
the reported ADRs (Lei et al., 2007). The Malaysian Adverse Drug Reaction 
Advisory Committee (MADRAC) was established under the Drug Control Authority 
(DCA) to monitor the safety profiles of drugs registered for use in Malaysia. The 
MADRAC provides the DCA with information pertaining to drug safety issues that 
occur locally and internationally. The National Drug Safety Monitoring Centre, 
which is the secretariat to MADRAC, was accepted as the 30th member of the WHO 
Safety Monitoring Program in 1990. Under this program, all ADR reports that have 
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been received and screened by MADRAC are submitted to the Uppsala Monitoring 
Centre in Sweden for inclusion in the WHO database.  
MADRAC also promotes ADR reporting in Malaysia, and provides 
information and advice to the DCA so that regulatory action can be taken based on 
the ADRs received. It also provides information to doctors, pharmacists and other 
healthcare professionals on ADRs and participates in the WHO ADR monitoring 
program.  A total of 7079 reports were received in the year 2010 which follows the 
ascending trend since year.  This figure is a 21% increase from year 2009.   Of the 
7079 reports received, 5976 reports (84.4%) were sent in by healthcare professionals 
from the government sector. This is an increase from last year’s 4698 reports from 
the government sector. The year 2010 also showed an increase (72.2%) in the 
number of ADR reports from private healthcare professionals (248 reports) compared 
to 2009 (144 reports). However, reports from Marketing Authorisation Holders 
(MAH) saw decreasing trend since year 2008. There was also an increase in the 
number of reports from the ‘Others’ category of reporters due to the higher number 
of reports submitted by nurses (338 reports) in accordance with the HPV national 
immunisation programme. Only 7 reports were submitted by consumers (MADRAC, 
2011). 
For all reports in year 2010, Selangor state contributed the highest number of 
ADR reports (1557; 22.0%), followed by Sabah (886; 12.52%) and Perak (845; 
11.9%). All other states exhibited an encouraging increase in the number of ADR 
reports submitted compared to year 2009 except for Johor, Melaka, Penang and 
Sarawak.  Classification of all reports according to SOC indicated that most adverse 
events reported were of the ‘Skin and Appendages Disorders’ SOC (20.2%) followed 
by ‘Body as a Whole – General Disorders’ SOC (16.7%) and ‘Central and 
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Peripheral Nervous System Disorder’ SOC (15.4%).  The reports involved 7753 
suspected products, of which 7134 (92.0%) were prescription products while 443 
(5.7%) were non-prescription products. The remaining 176 products (2.3%) involved 
were traditional products, cosmetic products, food products and unregistered 
products. Out of 5569 reports involving prescription products (excluding vaccines), 
more than half (56.9%) reported suspected drugs from the following 3 
pharmacological groups i.e. Cardiovascular (26.1%), Anti-infective (21.0%) and 
Analgesic (9.8%). This follows the trend in year 2009 where the top 3 major 
pharmacological groups were also Cardiovascular, Anti-infective and Analgesic.  In 
2010, there was a surge in reports for vaccines (1565 reports) compared to the figure 
in 2009 (242 reports). This is due to the launching of the national Human 
Papillomavirus (HPV) immunisation programme as well as the usage of H1N1 
vaccines in lieu of the H1N1 pandemic (MADRAC 2011). 
The ADR monitoring center in Malaysia also makes recommendations to the 
drug control authority on labeling changes, restrictions on use and suspension or 
withdrawal of drugs from the market. The center also carries out assessment of the 
signals through manual screening for potential signals, maintains the local database 
and the WHO database, and examines the medical literature to analyze and 
understand ADRs to be brought up for discussion with the advisory committee which 
is a subcommittee to the drug control authority in Malaysia. This committee 
convenes six times a year (Olsson, 1999). Figure 1 depicts the existing Malaysian 
Pharmacovigilance Program.  
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1.5.1 Weaknesses of the existing national pharmacovigilance program in 
Malaysia  
Although the existing pharmacovigilance program provided a strong base for drugs, 
drug safety and related activities it has few limitations. To name some, there is lack 
of awareness among health professionals regarding pharmacovigilance (Lei et al., 
2007). Similarly, there is difficulty in signal generation, because there is no national 
computerized database on drug prescriptions available in the country. In addition, 
there is a lack of information generated on genetic effects, social practices and drug 
interactions associated with drug use and there is a scarcity of reports about 
traditional and herbal drugs which are widely used.  The weaknesses seem to have 
originated from many angles; from the health professionals themselves, the 
government authority, and even the public.  
Another major limitation of the program is underreporting of ADRs. A study by 
Aziz et al. (2007), reported a high proportion (81.4%) of the respondents to have 
suspected an ADR but not reported it, while about 40% of the respondents were not 
even aware of the existence of the national reporting system in Malaysia. Other 
reasons for underreporting include uncertainty regarding the types of reaction to 
report, and a lack of awareness about the existence, function, and purpose of the 
national ADR reporting scheme (Aziz et al., 2007). Thus the number of ADR reports 
received by the national centre is extremely low; although, this number has increased 
in recent years. Another limitation is the lack of availability of an official consumer 
reporting system, which limits reporting occurring at the consumer level; and there is 
a lack of involvement of nursing staff in the ADR monitoring program.    
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1.6 Consumer reporting of adverse drug reactions  
In the global scenario , the existing ADR reporting system depends on spontaneous 
reports submitted by doctors, pharmacists, and pharmaceutical companies thus 
limiting the experiences from consumers. When consumers become involved in the 
process, they can reinforce their rights and ensure that they receive proper care in the 
future. Consumers’ experiences and views can be used as a good tool to provide 
information about ADRs. Reporting by consumers about the possible harmful effects 
of drugs has been in place for almost 15 years in developed countries. Such reporting 
increases the amount of knowledge, and serves as significant indicators of the 
damage resulting from incorrect usage of medicines (WHO Newsletter, 2000).  
However, only a few countries currently accept patient reports: Sweden (1978), 
Denmark (2003), Netherlands (2004), USA (1993), Canada (2003), Australia (2003), 
and UK (2005), (the year in the bracket means the year the system started) (de 
Langen et al., 2008, Medawar and Herxheimer, 2003). Consumers in these countries 
can report directly to medical agencies or indirectly through consumer organizations. 
They can also submit electronic reports or paper based reports and even telephone 
reports.   
Experience in the Netherlands obtained over a 3 year period showed that 
patient reporting can be a good source of information for drug safety monitoring and 
has qualitative and quantitative value.  An evaluation of the first six months of 
patient reporting via the yellow card scheme in the United Kingdom showed that 
there were no differences in the proportion of serious ADRs reported, compared with 
reports made by health professionals (McLay et al., 2006). 
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1.6.1 Benefits of incorporating consumers in ADR reporting programs 
As discussed previously in this chapter (Section 1.6), incorporation of consumers in 
ADR monitoring programs can provide immense strength to the programs. Some of 
the associated benefits are listed below (Blenkinsopp et al., 2007). 
 
1.6.1 (a) A new source of information for the regulatory bodies of medicines  
In many countries, consumer reporting has become an important source of new 
information on the harmful effects of drugs. Thus, it could benefit the regulatory 
authorities and is also an important source of information in clinical practice. 
 
1.6.1 (b) Disclosure of effects that were previously unknown  
When consumer reporting began in Denmark in 2003, the first year saw 149 reports 
from patients, which represented 7% of all reports. One-third of these consumer 
reports were about previously unknown adverse reactions, thus suggesting a vital 
role in identification of unknown ADRs. 
 
1.6.1 (c) Earlier reporting than health professionals 
In general, an ADR reported by health professional has to pass through various 
stages and finally reaches the regulatory authority. But consumer reports often reach 
the regulatory authority directly and hence make it an early source of documenting 
ADRs. A study from the Netherlands suggested that patients recognize and report 
adverse effects more quickly and earlier than health workers. 
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1.6.1 (d) Increase in the number of reports  
Often under-reporting of ADRs is a problem associated with many ADR reporting 
programs. Hence efforts are being done worldwide to enhance the number of reports. 
In this view consumer reporting is suggested to improve the number of ADR reports. 
For instance, in the United States consumer reporting began in 1993 and by 2004, 
reports by patients accounted for 15% of the total 24,553 reports (Ahmed et. al., 
2010). 
 
1.6.1 (e) Information on quality of life 
Often the ADR reports avail little information and do not mention the quality of life 
of the affected patient. Analysis of data in Sweden by the pharmacovigilance centre 
revealed that the style of reports made by patients differed from that of doctors, 
providing more information on the impact of medicine on the quality of life. Thus 
making consumer reporting important in understanding the ‘real suffering’ of the 
patients experiencing the ADR.  
 
1.6.1 (f) The reporting of serious adverse effects 
Data from the pharmacovigilance centre in the Netherlands noted that ADR reports 
by patients provide information on serious adverse effects (Blenkinsopp et al., 2007) 
which were often lacking during the health professional reporting. The patients 
reported 33 adverse reactions whereas only 12 out of these 33 reports were submitted 
by their healthcare providers. Upon analysis it was found that doctors reported 
serious adverse reactions, while the patients reported the reactions that made them 
stay in the hospital. 
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1.6.1 (g) Different style, but same quality  
There has been a concern that patients do not use the expressions/terms used by 
doctors and pharmacists. Therefore, the authorities noted that it is difficult to assess 
their reports and that it requires more time. However, there is no information in the 
literature about the time taken for analysis of these data. In addition, some authors 
have reported concerns about the quality of the reports and their credibility. 
However, the Dutch pharmacovigilance centre pointed out that patient reports have 
the same amount of information as those provided by health workers (Blenkinsopp et 
al., 2007). 
 
1.6.1 (h) Reports by elderly people  
A group of Belgian authors compared reports made by 168 elderly patients and those 
made by their healthcare providers (Blenkinsopp et al., 2007). The authors asked the 
patients to explain the reason for their admission to hospital. 
 
1.6.1 (i) Patients report effects that have a strong relationship with drugs   
Researchers from the US interviewed 198 patients by telephone and the results of 
this study indicated that health workers reported only half of the complaints made by 
the patients (Blenkinsopp et al., 2007). 
 
1.7 Problem statement and rationale  
1.7.1 Problem statement 
Malaysia, a developing country in South East Asia has established its own national 
pharmacovigilance program. The pharmacovigilance program in Malaysia, however, 
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has limited coverage and receives only a limited number of ADR reports. There is 
still room for improvement as regards the program.  The problem statement of this 
study is derived considering the major weaknesses of the current program in the 
country. First, it is observed that there is a lack of awareness among health 
professionals with regard to the existence, function, and purpose of ADR reporting 
and pharmacovigilance. There is also no national computerized database on drugs 
prescribed, making signal generation difficult. There is less involvement of 
pharmaceutical industries on drug safety matters and the reason for this is not known. 
The next weakness is the lack of information on the genetic effects and social 
practices and drug interactions associated with drug use.  ADRs to the widely-used 
traditional and herbal drugs have been less reported adding to the underreporting 
plaguing the country.  Finally, and also perhaps most importantly, there has been no 
involvement of nursing staff and consumers in the ADR reporting program. These 
individuals are more directly involved with handling and consuming medicines. 
 
1.7.2 Rationale for the study 
Considering these complications and the limitations of the country’s 
pharmacovigilance program, the rationale of this study was that the involvement of 
patients (consumers) in the process of drug safety monitoring in Malaysia will bring 
more benefits and advantages to the existing system. Also, knowledge about ADRs 
will be acquired by the persons involved, be it the patients themselves, the nurses, the 
healthcare practitioners, and even the authorities themselves. The findings of this 
study may also reduce underreporting, as the more knowledgeable the person is, the 
more he or she knows the importance of ADR reporting and how to report ADRs.  
The quality of life will be further improved, and consumer rights will be promoted. 
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In addition, this study will help to increase the efficiency of Malaysia’s healthcare 
system and medicines use process. Increasing the efficiency will allow healthcare 
professionals to focus on the detection of counterfeit medicines, which is another 
problem in the country.  
 
Malaysia needs to involve consumers in drug safety issues due to the following 
reasons and the noticeable trends mentioned below that clearly make the justification 
of this study:   
1.  The numbers of reports given by doctors, pharmacists and dentists is still small.  
2.  Underreporting of ADRs is present. 
3.  There are substantial limitations on the existing reporting system. 
4.  Increased use of medicines without healthcare professionals’ supervision. 
5.  Growth in use of unconventional products (herbal remedies), and 
6.  Promotion of consumer rights. 
 
Patients and consumers as well as health professionals have the right to be involved 
and to report their experiences and sufferings as a result of these adverse effects 
which threaten their health and their lives. When consumers are involved in the 
process, their rights are subsequently reinforced thus achieving justice in the 
healthcare delivery.  
 
1.8 Research objectives 
The objectives of this study are as follows: 
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1. To compare the structure, process and outcome of existing drug safety systems 
between Malaysia and  two other countries (Sweden and Australia) that have adopted 
consumer reporting of ADRs,   
2. To evaluate the knowledge, attitudes and experiences of consumers towards and 
reporting of ADRs,  
3. To evaluate the perceptions of health care professionals (general practitioners and 
community pharmacists in Penang) towards consumer reporting of ADRs, and 
4. To evaluate the impact on pharmacovigilance, as well as analyze and assess 
consumer reports in the university-based pharmacovigilance centre during the 
operation of the Pilot Program in the USM’s University Wellness Centre (UWC), 
with the following aims:  
  a. To evaluate the knowledge, attitude and practice (KAP) among 
healthcare professionals in UWC towards pharmacovigilance and ADR 
reporting and the main reasons for underreporting, and  
  b. To assess the reporting rate among healthcare professionals in the 
UWC by conducting educational interventions.  
 
1.9 Research questions 
  Based on the literature survey and conceptual framework, this study aims to 
answer some relevant and significant research questions: 
1.  What are the differences in structures, process and outcome between drug safety 
monitoring systems in Malaysia, Sweden and Australia? 
2.  What are the level of knowledge, attitudes and practice among Malaysian consumers 
about adverse drug reactions in general and consumer reporting of adverse drug 
reactions? 
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3.  What are the perceptions among Malaysian healthcare professionals regarding 
consumer reporting? 
4.  What is the impact of setting up a university-based pharmacovigilance center in the 
University Wellness Center at Universiti Sains Malaysia?     
 
1.10  Contributions of the study findings   
As consumer reporting is important for achieving better healthcare standards in 
Malaysia, this study seeks to highlight the importance of consumer reporting among 
different stakeholders as in the following:  
1. Consumers are active players in drug safety and key stakeholders in relation to 
pharmacovigilance and can actively contribute through an integrated and efficient 
reporting system. 
2. Direct consumer reporting is an essential tool to empower consumers and improve 
their involvement in the management of their own health. 
3.  With consumer reporting, ADRs will be detected earlier, and more ADRs would be 
reported especially those associated with over-the-counter medicines. 
4. Consumer reporting can be a useful method to overcome underreporting of ADRs. 
5. Consumer reporting can be a good solution for the limitations of the existing ADR 
monitoring system that is based on health professionals’ reports. 
6. Involvement of consumers in ADR reporting will promote consumer rights. 
7. Consumer reporting cannot replace the existing system, but can complement and 
strengthen it. 
8. It will help in detection of counterfeit and unsafe marketed drugs. 
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A significant message from the study is the importance of the healthcare 
professionals and need for a broader healthcare system in supporting patients 
(consumers) to be involved in enhancing drug safety. The professionals need to be 
receptive and open to patients’ concerns and questions, and to facilitate patients’ 
attempts to be involved in their care. The findings suggest that care providers should 
not take concerns voiced by patients lightly. These professionals also need to be 
properly educated about ADR reporting. A positive patient professional relationship 
is important for patients to be able to contribute to the improvements in healthcare 
safety. It also suggests the need for appropriate attitudes and good communication 
skills among professionals and patients. 
This study also offers an interesting insight about the power of the consumers. 
In terms of ADR reporting, consumers are the most valid reporters of ADRs as they 
are the ones experiencing any ADRs that occur.  This study also addressed some of 
the problems mentioned previously in the study (lack of belief that ADR reporting 
can help consumers in obtaining safer drugs and leading to better quality of life; 
customers not knowing how to write proper, valid reports; not being clear of the 
purpose of the reports, etc., to name a few), and justifies that consumers would be 
able to contribute to the ADR reporting system in a successful manner. 
Overall, the study has also given a new meaning to the word 
pharmacovigilance.  The public, the medical staff, MADRAC as well as the 
government, through various ministries, bodies and organizations must all work 
together to make sure that ADRs are responded to and channeled properly.   
Having outlined some lessons learnt about consumer reporting, safe and 
effective drug therapy demands profound knowledge of every drug product being 
prescribed. Consumer reporting and pharmacovigilance should complement each 
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other to enhance the standard of healthcare and better the medical system in the 
country. If these essentials are observed, as well as practiced and supported, most 
drug-induced diseases and most drug-related malpractice litigations can perhaps be 
avoided, and human beings get to enjoy at least one basic human right to which they 
are entitled, that is ‘the right to health’.      
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CHAPTER 2  
LITERATURE REVIEW 
 
2.1 Adverse drug reactions  
There has been a growing trend in recent years on reporting of the Adverse Drug 
Reactions (ADRs). The majority of the drug regulatory agencies around the world 
have developed reliance on the detection and reporting of suspected ADRs for 
improving medicine safety in the population.   
An adverse event (AE) connotes ‘any untoward medical occurrence that may 
arise during the treatment with a pharmaceutical product but which does not 
necessarily have a causal relationship with the treatment’.  Perhaps, a better 
definition compared to WHO (2002) and the new Adverse Drug Reaction definition 
was given by Edward and Aronson as:    
‘An appreciable harmful or unpleasant reaction, resulting from an intervention 
related to the use of a medicinal product which predicts hazard from future 
administration and warrants prevention or specific treatment, or alteration of the 
dosage regime or withdrawal of the product’. (Edwards and Aronson, 2000)  
ADRs are known to cause morbidity, mortality, increase duration of hospital 
stay and the cost of hospitalization.  Lazarou et al. (1998) even pointed out that 
ADRs related to prescribed medicines are among the fourth to sixth most common 
causes of deaths in the US.  Statistics show that 300,000 patients are hospitalized 
every year due to ADRs in the US  (Atkin and Shenfiled, 1998).  Shapiro (1971) has 
reported 160,000 deaths in the US annually due to ADRs and this figure may not be 
very different from what happens in other countries.  Moving to the world at large, 
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Einarson (1993) draws attention to the fact that 0.2-21.7% of hospital admissions are 
due to ADRs.   
ADRs are classified into four types, which are adapted from the original 
classification by Rawlins (1981): Type A is ‘Augmented,’ Type B ‘Bizarre,’ Type C 
‘Cumulative,’ and Type D ‘Delayed.’  A deeper understanding on the nature of ADRs 
reveals them to be ‘dose-related’, ‘time-related’, and ‘susceptibility-based’.  As per 
the Dots classification system of ADRs, which is based on time course and 
susceptibility as well as dose responsiveness, ADRs that are dose-related contain 
some toxic effects, where the ADRs occur at doses higher than the normal 
therapeutic dose. Some ADRs may happen at standard therapeutic doses and the 
higher susceptibility reactions occur at subtherapeutic doses in susceptible patients.  
The time-related nature of ADRs is seen in the ADRs that occur at any time during 
the treatment given, causing various reactions.   
Some ADRs are categorized as ‘rapid reactions’ that occur when a drug is 
administered too fast. Similarly, ‘early reactions’ occur early on in the treatment and 
then abate with continuing treatment. ‘Intermediate reactions’ occur after some delay, 
but if reaction does not occur after a certain time little or no risk exists. The ‘late 
reaction’, in turn, suggests that the risk of ADR increases with continued or repeated 
exposure, including withdrawal reactions.  ‘Delayed reactions’ occur after a time 
period following exposure, even if the drug is withdrawn before the ADR occurs. 
Some individuals are known to possess a raised susceptibility towards occurrence of 
ADRs. The various factors that are associated with increased susceptibility of ADRs 
include genetic variation, age, sex, altered physiology, exogenous factors 
(interactions), and disease (Edwards and Aronson, 2000).  
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The American Food and Drug Administration defines a serious adverse event as one 
when the patient outcome is one of the following: 
 Death 
 Life-threatening 
 Hospitalization (initial or prolonged) 
 Disability - significant, persistent, or permanent change, impairment, damage 
or disruption in the patient's body function/structure, physical activities or quality of 
life. 
 Congenital anomaly 
 Requires intervention to prevent permanent impairment or damage. 
  
2.2 Consumer reporting of ADRs  
The renewal of interest in consumer ADR reporting is probably due to the 
decreasing number of ADR reports from healthcare professionals. Consumer self-
monitoring of drugs has been used in the past, but only focusing on specific drugs of 
concern and has been argued to be essential to obtain trustworthy reports of effects 
from central nervous system drugs (Fisher, 1995). In general, consumer reporting is 
important to gain direct access to patients’ views on the medicine prescribed, to grant 
people the opportunity to more actively contribute to medicine regulation, for the 
people to have more choice, and greater access to medicines. It is also important 
considering two growing trends - the increased use of medicines without supposed 
supervision from the professionals and the growing use of unconventional products 
(herbal remedies is one example). Patients’ reports can capture personal experiences 
in a way that professional reports cannot. The ‘richness’ of such reports can serve as 
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a guide to relevant authorities and can focus attention towards ADRs normally 
dismissed as trivial by health professionals.   
Blenkinsopp et al. (2007) published a systemic review on patient reporting of 
suspected ADRs. Authors provided more evidence on the importance of consumer 
reporting of ADRs and justified advantages, from international experience, regarding 
consumer reporting. They concluded that there is lack of publications about patients’ 
reporting of ADRs in the literature, and if available, most published studies were 
very small in terms of duration and number of patients (Blenkinsopp, 2007). 
Qualitative examination of ADRs reported by patients has shown them to be rich in 
terms of their description of nature, severity and significance of reactions (Medawar 
and Herxheimer, 2003). 
Underreporting of ADRs was recognized as a limitation of the ADR reporting 
program in Sri Lanka and authors from the same country suggested consumer 
reporting to be the best method for developing countries to overcome underreporting 
of ADRs. They also hypothesized that consumer reporting can complement the 
existing system of ADR reporting which is mainly physician and pharmacist centered 
(Fernandopulle and Weerasuriya, 2003). 
Van Grootheest and his colleagues published a review on patients’ roles in 
reporting ADRs. They discussed the involvement of patients in the reporting of 
ADRs. Authors concluded that people should positively value patients’ involvement 
in drug therapy and their concern regarding possible ADRs (van Grootheest and de 
Jong-van den Berg, 2004). This review discusses the involvement of patients in the 
reporting of adverse drug reactions (ADRs). Patients benefit from drugs but also 
experience their adverse effects. Since concerns about the safety of drugs are also 
patients' concerns, the patient could also play a part in decreasing the risks of drug 
